In re: Application Prieels. J.P et al., et al.

Group Art Unit: 1203 (Tent.)

3. (As amended) A vaccine composition as claimed in claim 1 [or 2] capable of invoking a cytolytic T cell response in a mammal to the antigen or antigenic composition.

4. (As amended) A vaccine composition as claimed in [any of claims 1 to 3] claim 1 capable of stimulating interferon γ production.

5. (As amended) A vaccine composition as claimed in [any of claims 1 to 4] claim 2 wherein the ratio of QS21:3D-MPL is from 1:1 to1:2.5.

6. (As amended) A vaccine composition as claimed in [any of claims 1 to 5] claim 1 comprising an antigen or antigenic composition derived from [any] the group consisting of Human Immunodeficiency Virus, Feline Immunodeficiency Virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Hepatitis A, B, C or E, Respiratory Syncytial virus, human papilloma virus, Influenza virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium [or] and Toxoplasma.

7. (As amended) A vaccine as claimed in [any of] claim 1 [to 5] wherein the antigen is a tumour antigen.

8. (As amended) Use of composition as defined in [any of claims 1 to 5] claim 1 for the manufacture of a vaccine for the prophylactic treatment of viral, bacterial, or parasitic infections.

9. (As amended) Use of composition as defined in [any of claims 1 to 5] claim 1 for the manufacture of a vaccine for the immunotherapeutic treatment of viral, bacterial, parasitic infections or cancer.

10. (As amended) A method of treating a mammal suffering from or susceptible to a pathogenic infection comprising the administration of a safe and effective amount of a composition according to [any of claims 1 to 5] claim 1.

